Compare FOSL & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOSL | TNXP |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.1M | 220.5M |
| IPO Year | N/A | 2008 |
| Metric | FOSL | TNXP |
|---|---|---|
| Price | $4.02 | $13.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 870.5K | 348.1K |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $566.15 |
| Revenue Next Year | $1.66 | $36.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $0.86 | $13.07 |
| 52 Week High | $5.01 | $69.65 |
| Indicator | FOSL | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 43.99 |
| Support Level | $3.25 | $13.32 |
| Resistance Level | $4.23 | $20.36 |
| Average True Range (ATR) | 0.34 | 1.02 |
| MACD | -0.07 | 0.15 |
| Stochastic Oscillator | 21.43 | 16.62 |
Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.